Combination treatment with docetaxel and histone deacetylase inhibitors downregulates androgen receptor signaling in castration-resistant prostate cancer
暂无分享,去创建一个
Dong Eun Kim | E. Choi | Choung-Soo Kim | J. Hwang | Seong-Yun Jeong | Sang eun Park | Yunlim Kim | Seong‐Yun Jeong | Y. Jung | Ha-Gyeong Kim | S. Jeong
[1] E. Iorns,et al. Replication study: androgen receptor splice variants determine taxane sensitivity in prostate cancer , 2018, PeerJ.
[2] H. Lee,et al. A novel HDAC inhibitor, CG200745, inhibits pancreatic cancer cell growth and overcomes gemcitabine resistance , 2017, Scientific Reports.
[3] Ming-Fong Lin,et al. Histone deacetylase inhibitors in castration-resistant prostate cancer: molecular mechanism of action and recent clinical trials , 2015, Therapeutic advances in urology.
[4] Jun Luo,et al. Androgen Receptor Splice Variant 7 and Efficacy of Taxane Chemotherapy in Patients With Metastatic Castration-Resistant Prostate Cancer. , 2015, JAMA oncology.
[5] D. Tindall,et al. Are androgen receptor variants a substitute for the full-length receptor? , 2015, Nature Reviews Urology.
[6] W. Isaacs,et al. AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. , 2014, The New England journal of medicine.
[7] R. Ferraldeschi,et al. Evolution of androgen receptor targeted therapy for advanced prostate cancer , 2014, Nature Reviews Clinical Oncology.
[8] E. Wiemer,et al. Cross-resistance between taxanes and new hormonal agents abiraterone and enzalutamide may affect drug sequence choices in metastatic castration-resistant prostate cancer. , 2013, European journal of cancer.
[9] Jun Luo,et al. Decoding the androgen receptor splice variants , 2013, Translational andrology and urology.
[10] H. Scher,et al. A phase 2 study of intravenous panobinostat in patients with castration-resistant prostate cancer , 2013, Cancer Chemotherapy and Pharmacology.
[11] W. Oh,et al. Targeting the androgen receptor signalling axis in castration‐resistant prostate cancer (CRPC) , 2012, BJU international.
[12] P. Albers,et al. Current second-line treatment options for patients with castration resistant prostate cancer (CRPC) resistant to docetaxel. , 2012, Urologic oncology.
[13] S. Jang,et al. A novel histone deacetylase inhibitor, CG200745, potentiates anticancer effect of docetaxel in prostate cancer via decreasing Mcl-1 and Bcl-XL , 2012, Investigational New Drugs.
[14] P. Nelson,et al. Distinct transcriptional programs mediated by the ligand-dependent full-length androgen receptor and its splice variants in castration-resistant prostate cancer. , 2012, Cancer research.
[15] A. Gao,et al. Mechanisms of persistent activation of the androgen receptor in CRPC: recent advances and future perspectives , 2012, World Journal of Urology.
[16] B. Mellado,et al. Identification of Docetaxel Resistance Genes in Castration-Resistant Prostate Cancer , 2011, Molecular Cancer Therapeutics.
[17] D. Tindall,et al. Alternatively spliced androgen receptor variants. , 2011, Endocrine-related cancer.
[18] N. Bander,et al. Taxane-induced blockade to nuclear accumulation of the androgen receptor predicts clinical responses in metastatic prostate cancer. , 2011, Cancer research.
[19] K. Fizazi,et al. Targeting Continued Androgen Receptor Signaling in Prostate Cancer , 2011, Clinical Cancer Research.
[20] C. Bevan,et al. Androgen Receptor Signalling in Prostate Cancer: The Functional Consequences of Acetylation , 2010, Journal of Biomedicine and Biotechnology.
[21] Dong Eun Kim,et al. Histone deacetylase inhibitor potentiates anticancer effect of docetaxel via modulation of Bcl-2 family proteins and tubulin in hormone refractory prostate cancer cells. , 2010, The Journal of urology.
[22] H. Scher,et al. A phase I study of oral panobinostat alone and in combination with docetaxel in patients with castration-resistant prostate cancer , 2010, Cancer Chemotherapy and Pharmacology.
[23] David C. Smith,et al. Vorinostat in advanced prostate cancer patients progressing on prior chemotherapy (National Cancer Institute Trial 6862) , 2009, Cancer.
[24] S. Steinberg,et al. Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[25] N. Bander,et al. Docetaxel down‐regulates the expression of androgen receptor and prostate‐specific antigen but not prostate‐specific membrane antigen in prostate cancer cell lines: Implications for PSA surrogacy , 2009, The Prostate.
[26] K. Chin,et al. Protein Acetylation and Histone Deacetylase Expression Associated with Malignant Breast Cancer Progression , 2009, Clinical Cancer Research.
[27] Zhiyong Guo,et al. A novel androgen receptor splice variant is up-regulated during prostate cancer progression and promotes androgen depletion-resistant growth. , 2009, Cancer research.
[28] L. Borsu,et al. Histone deacetylases are required for androgen receptor function in hormone-sensitive and castrate-resistant prostate cancer. , 2009, Cancer research.
[29] Yong J. Lee,et al. Pretreatment of docetaxel enhances TRAIL‐mediated apoptosis in prostate cancer cells , 2008, Journal of cellular biochemistry.
[30] H. Scher,et al. Targeting the androgen receptor pathway in prostate cancer. , 2008, Current opinion in pharmacology.
[31] D. Tindall,et al. Splicing of a novel androgen receptor exon generates a constitutively active androgen receptor that mediates prostate cancer therapy resistance. , 2008, Cancer research.
[32] T. Kuzel,et al. Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[33] H. Scher,et al. Biology of progressive, castration-resistant prostate cancer: directed therapies targeting the androgen-receptor signaling axis. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[34] D. Tindall,et al. Androgen receptor signaling in androgen-refractory prostate cancer. , 2001, Journal of the National Cancer Institute.
[35] A. Riegel,et al. Inhibition of histone deacetylation augments dihydrotestosterone induction of androgen receptor levels: an explanation for trichostatin A effects on androgen-induced chromatin remodeling and transcription of the mouse mammary tumor virus promoter. , 1999, Experimental cell research.
[36] S. Dehm,et al. Constitutive activity of the androgen receptor. , 2014, Advances in pharmacology.
[37] I. Tannock,et al. Drug resistance in metastatic castration-resistant prostate cancer , 2011, Nature Reviews Clinical Oncology.
[38] D. Qian,et al. Cancer esearch apeutics , Targets , and Chemical Biology ulin-Targeting Chemotherapy Impairs Androgen R eptor Activity in Prostate Cancer , 2010 .
[39] R. Vessella,et al. Ligand-independent androgen receptor variants derived from splicing of cryptic exons signify hormone-refractory prostate cancer. , 2009, Cancer research.
[40] S. Minucci,et al. Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer , 2006, Nature Reviews Cancer.
[41] D. Bissett,et al. Taxol and taxotere--current status and future prospects. , 1993, European journal of cancer.
[42] T. Chou,et al. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. , 1984, Advances in enzyme regulation.